Physician profile
Jonathan Weiss
NPI 1225327844
$3,392.11
in general payments reported to CMS, 2019-2025
15 companies · $365 in 2025
The $365 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,547 · 2020: $12.44 · 2021: $82.64 · 2022: $192 · 2023: $22.76 · 2024: $171 · 2025: $365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $473 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $473.21 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermira, INC. | $2,500.00 | 2019 | |
| Abbott Laboratories | $175.01 | 2022 | |
| Janssen Biotech, INC. | $168.76 | 2022-2025 | Tremfya |
| Arcutis Biotherapeutics, INC. | $105.25 | 2024 | Zoryve |
| Genzyme Corporation | $98.26 | 2025 | |
| Sanofi-Aventis U.S. LLC | $85.00 | 2025 | |
| Ucb, INC. | $82.64 | 2021 | |
| Galderma Laboratories, L.P. | $39.51 | 2019-2020 | |
| Leo Pharma INC. | $30.70 | 2025 | Adbry, Spevigo, Anzupgo |
| Incyte Corporation | $27.08 | 2025 | Opzelura |
| Glaxosmithkline, LLC. | $22.76 | 2023 | Shingrix |
| Almirall LLC | $19.50 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.36 | 2025 | Caplyta |
| Sun Pharmaceutical Industries INC. | $18.28 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Weiss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.